Stay in Touch
To keep in touch, please sign up to the Milltrust Ventures Newsletter for our latest news and insights.
Bill Enright, CEO of Vaccitech, one of Milltrust’s British Innovation Fund’s investee companies, discusses how the company is helping the fight against COVID-19 through its research in developing a vaccine.
Vaccitech is an investee company of Milltrust’s British Innovation Fund through our early participation in Oxford Sciences Innovation. The company is working on a program supported by the UK Government at the University of Oxford where co-founder Professor Sarah Gilbert has advised that she could be close to delivering a vaccine of a COVID-19 specific vector, and clinical trials are underway with over 500 patients. Vaccitech has a non-exclusive license to this work, and FDA approval is being sought.
A unique element of the work at Vaccitech is the T cell component to protection, which no other research group is measuring. The Vaccitech vaccine is showing significant efficacy in stimulating high levels of T cells needed to protection whereas DNA, RNA and protein-based vaccines do not.
The series A post money valuation of the company was 86 million USD and the company is now seeking a minimum of 55 million USD which will fund the COVID-19 vaccine development, in addition to its other ongoing work, allowing the firm to manufacture tens of millions of doses later this year.
Vaccitech has also promising clinical data from a phase 1 trial for MERS and is scheduled to commence an additional study in Saudi Arabia as soon as travel restrictions permit.
See 6 min webinar summary video below
For more information, please contact [email protected] or visit www.milltrust.com